Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed t...
Q1 2026
May 8, 2026
FY 2025
Mar 9, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 5, 2025